Morquio-like dysostosis multiplex presenting with neuronopathic features is a distinct GLB1-related phenotype

• Autor(a) principal: Ipsiroglu, Sylvia Stockler
• Data de Publicação: 2021
• Outros Autores: Yazdanpanah, Nahid, Yazdanpanah, Mojgan, Popurs, Marioara Moisa, Yuskiv, Nataliya, Santos, Mara Lúcia Schmitz Ferreira, Kim, Chong Ae, Souza, Carolina Fischinger Moura de, Lourenço, Charles Marques, Steiner, Carlos Eduardo, Federhen, Andressa, Giugliani, Luciana, Pereira, Débora Maria Bastos, Duran Carabali, Luz Elena, Giugliani, Roberto
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/234474
• topic: Mucopolissacaridose IV; Distonia; Sulfato de ceratano; beta-Galactosidase; Gangliosidose GM1; Osteocondrodisplasias; Dystonia; Keratan sulfate; Mucopolysaccharidosis type IVB; Spondyloepiphyseal dysplasia; Type 3 GM1 gangliosidosis; β-galactosidase

Background Morquio B disease (MBD) is a distinct GLB1-related dysostosis multiplex presenting a mild phenocopy of GALNS-related Morquio A disease. Previously reported cases from European countries carry the W273L variant on at least one GLB1 allele and exhibit a pure skeletal phenotype (pure MBD). Only a minority of MBD cases have been described with additional neuronopathic findings (MBD plus). Objectives and Methods With the aim to further describe patterns of MBD-related dysostosis multiplex, we analyzed clinical, biochemical, and genetic features in 17 cases with GLB1-related dysostosis multiplex living and diagnosed in Brazil. Results About 14 of the 17 individuals had three or more skeletal findings characteristic of Morquio syndrome. Two had no additional neuronopathic features (pure MBD) and 12 exhibited additional neuronopathic features (MBD plus). Three of the 17 cases had mild dysostosis without distinct features of MBD. Seven of the 12 MBD plus patients had signs of spinal cord compression (SCC), as a result of progressive spinal vertebral dysostosis. There was an age-dependent increase in the number of skeletal findings and in the severity of growth impairment. GLB1 mutation analysis was completed in 10 of the 14 MBD patients. T500A occurred in compound heterozygosity in 8 of the 19 alleles. Conclusion Our study extends the phenotypic spectrum of GLB1-related conditions by describing a cohort of patients with MBD and GM1-gangliosidosis (MBD plus). Targeting the progressive nature of the skeletal manifestations in the development of new therapies for GLB1-related conditions is warranted.